|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Impact of old age on clinical and angiographic characteristics of coronary artery spasm as assessed by acetylcholine provocation test显示文摘吸烟并且另外的风险因素作为变体咽峡炎或冠的动脉痉挛(CAS ) 的重要因素众所周知。然而,与冠的动脉痉挛上的年龄有关的临床的特征是 evaluated.MethodsWe 很少与不足道的冠的动脉损害评估了 3155 个连续病人。病人们经历了醋胆素(Ach ) 为 CAS 的正式就职的挑衅测试。CAS 是被定义 >70% 钠在 Ach 期间变窄冠的动脉挑衅测试。Ach 挑衅测试的结果在年龄组之中被比较;< 45 年(组 1 ) , 45-54 年(组 2 ) , 55-64 年(组 3 ) ,和 .ResultsOlder 病人有高血压,糖尿病,而是更低的发生的更高的发生的 65 年(组 4 ) 与更年轻的病人相比当前的吸烟、男性别评价。积极 Ach 挑衅测试发现经常与老化被显示出(47.36% 对 58.3% 对 62.6% 对 61.5% ;P < 0.001 ) 。Multivariate 逻辑分析证明年龄,男性,和心肌的桥牌是学习显示出的在场的 Ach 挑衅 test.ConclusionOur 导致的 CAS 的独立预言者老年是为导致 Ach 的重要冠的动脉痉挛的独立预言者。 | Woong Gil Choi Soo Hyun Kim Seung-Woon Rha Kang-Yin CHEN Yong-Jian LI Byoung Geol Choi Se Yeon Choi Jin Won Kim Eung Ju Kim Chang Gyu Park Hong Seog Seo Dong Joo Oh | 2016 | Journal of Geriatric Cardiology2016，13，10： | 7 |
| 2 | Prevalence of premature ejaculation in young and middle-aged men in Korea: a multicenter intemet-based survey from the Korean Andrological Society显示文摘 | Hyun Jun Park Jong Kwan Park Kwangsung Park Sung Won Lee Sae-Woong Kim Dae Yul Yang DU Geon Moon Kweon-Sik Min Ki-Hak Moon Sang-Kuk Yang Jae Seog Hyun Nam Cheol Park | 2010 | Asian Journal of Andrology2010，12，6： | 5 |
| 3 | Calcium channel blocker monotherapy versus combination with reninangiotensin system inhibitors on the development of new-onset diabetes mellitus in hypertensive Korean patients显示文摘Background In real practice, two or more antihypertensive drugs are needed to achieve target blood pressure. We investigated the comparative beneficial actions of combination therapy of renin-angiotensin system inhibitors (RASI), with calcium channel blockers (CCB) over CCB monotherapy on the development of new-onset diabetes mellitus (NODM) in Korean patients during four-year follow-up periods. Methods A total of 3208 consecutive hypertensive patients without a history of diabetes mellitus who had been prescribed CCB were retrospectively enrolled from January 2004 to December 2012. These patients were divided into the two groups according to the additional use of RASI (the RASI group, n = 1221 and the no RASI group, n = 1987). Primary endpoint was NODM, defined as a fasting blood glucose ≥ 126 mg/dL or hemoglobin A1c ≥ 6.5%. Secondary endpoint was major adverse cardiac events (MACE) defined as total death, myocardial infarction (MI) and percutaneous coronary intervention (PCI). Results After propensity score-matched (PSM) analysis, two propensity- matched groups (939 pairs, n = 1878, C-statistic = 0.743) were generated. The incidences of NODM (HR = 1.009, 95% CI: 0.700–1.452, P = 0.962), MACE (HR = 0.877, 95% CI: 0.544–1.413, P = 0.589), total death, MI, PCI were similar between the two groups after PSM during four years. Conclusions The use of RASI in addition to CCB showed comparable incidences of NODM and MACE compared to CCB monotherapy in non-diabetic hypertensive Korean patients during four-year follow-up period. However, large-scaled randomized controlled clinical trials will be required for a more definitive conclusion. | Yong Hoon Kim Ae-Young Her Seung-Woon Rha Byoung Geol Choi Se Yeon Choi Jae Kyeong Byun Yoonjee Park Dong Oh Kang Won Young Jang Woohyeun Kim Woong Gil Choi Tae Soo Kang Jihun Ahn Sang-Ho Park Ji Young Park Min-Ho Lee Cheol Ung Choi Chang Gyu Park Hong Seog Seo | 2019 | Journal of Geriatric Cardiology2019，16，6： | 3 |
| 4 | Phase Ⅱ study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma:consortium for improving survival of lymphoma(CISL)study显示文摘Background:The response rate and survival improvement for rituximab,a CD20-targeting monoclonal antibody,have been demonstrated in marginal zone lymphoma(MZL)as monotherapy and in combination with chemotherapeutic regimens,yet relapses still occur despite treatment completion.Thus,extending the period of remission in MZL patients remains an essential goal.This multicenter,single-arm,open-label phase II study evaluated the survival efficacy of 2 years of rituximab-maintenance therapy in patients with stage III-IV CD20-positive MZL who had responded to first-line R-CVP(rituximab,cyclophosphamide,vincristine,and prednisolone).The objective of this study was to determine whether rituximab maintenance following R-CVP warrants further investigation.Methods:Prior to rituximab-maintenance therapy,patients received 6-8 cycles of first-line R-CVP therapy for stage III-IV MZL.Rituximab(375 mg/m^(2)),cyclophosphamide(750 mg/m^(2)),and vincristine(1.4 mg/m^(2);maximum 2 mg)were administered via an intravenous infusion on day 1 of each 3-week cycle,while oral prednisolone(100 mg)was given on days 1-5 of each 3-week cycle.The patients who achieved complete response(CR),partial response(PR),or stable disease(SD)to R-CVP treatment,were prescribed rituximab-maintenance therapy which was administered intravenously at a dose of 375 mg/m^(2) every 8 weeks for up to 12 cycles.The primary endpoint was progression-free survival(PFS).Secondary endpoints were overall survival(OS)and treatment safety.Results:47 patients were enrolled,of whom,45(96%)received rituximab-maintenance treatment.Fifteen(33%)patients had nodal MZL.Following R-CVP first-line therapy,20(44%),22(49%),and 3(7%)patients achieved CR,PR,and SD,respectively.After a median follow-up of 38.2 months,their observed 3-year PFS rate was 81%.During the rituximab-maintenance,6 PR and 1 SD patients achieved CR following the administration of R-CVP.Elevated LDH and the presence of B symptoms were found to be significant prognostic factors for PFS(P=0.003)and demonstrated a 3-year OS rate of 90%.Rituximab-maintenance therapy was well tolerated,and the common treatment-emergent adverse events were sensory neuropathy(18%),myalgia(13%),fatigue(9%),and neutropenia(9%).Conclusion: Rituximab-maintenance therapy following first-line R-CVP demonstrated good PFS in patients with stage III-IV MZL, in addition to a favorable toxicity profile. | Sung Yong Oh Won Seog Kim Jin Seok Kim Seok Jin Kim Dok Hyun Yoon Deok-Hwan Yang Won Sik Lee Hyo Jung Kim Ho-Young Yhim Seong Hyun Jeong Jong Ho Won Suee Lee Jee Hyun Kong Sung-Nam Lim Jun Ho Ji Kyung A.Kwon Gyeong-Won Lee Jae Hoon Lee Ho Sup Lee Ho-Jin Shin Cheolwon Suh | 2019 | Cancer Communications2019，39，1： | 2 |
| 5 | Five-year clinical outcomes of first-generation versus second-generation drug-eluting stents following coronary chronic total occlusion intervention显示文摘Background There are limited data comparing long-term clinical outcomes between first-generation (1G) and second-generation (2G) drug-eluting stents (DESs) in patients who underwent successful percutaneous coronary intervention (PCI) for coronary chronic total occlusion (CTO) lesion. Methods A total of 840 consecutive patients who underwent PCI with DESs for CTO lesion from January 2004 to November 2015 were enrolled. Finally, a total of 324 eligible CTO patients received 1G-DES (Paclitaxel-eluting stent or Sirolimus-eluting stent, n = 157) or 2G-DES (Zotarolimus-eluting stent or Everolimus-eluting stent, n = 167) were enrolled. The clinical endpoint was the occurrence of major adverse cardiac events (MACE) defined as all-cause death, recurrent myocardial infarction (re-MI), total repeat revascularization [target lesion revascularization (TLR), target vessel revascularization (TVR), and non-TVR]. We investigated the 5-year major clinical outcomes between 1G-DES and 2G-DES in patient who underwent successful CTO PCI. Results After propensity score matched (PSM) analysis, two well-balanced groups (111 pairs, n = 222, C-statistic = 0.718) were generated. Up to the 5-year follow-up period, the cumulative incidence of all-cause death, re-MI, TLR, TVR and non-TVR were not significantly different between the two groups. Finally, MACE was also similar between the two groups (HR = 1.557, 95% CI: 0.820–2.959, P = 0.176) after PSM. Conclusions In this study, 2G-DES was not associated with reduced long-term MACE compared with 1G-DES following successful CTO revascularization up to five years. | Yong Hoon Kim Ae-Young Her Seung-Woon Rha Byoung Geol Choi Se Yeon Choi Jae Kyeong Byun Yoonjee Park Dong Oh Kang Won Young Jang Woohyeun Kim Ju Yeol Baek Woong Gil Choi Tae Soo Kang Jihun Ahn Sang-Ho Park Ji Young Park Min-Ho Lee Cheol Ung Choi Chang Gyu Park Hong Seog Seo | 2019 | Journal of Geriatric Cardiology2019，16，8： | 1 |
| 6 | An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach显示文摘 | Sung Kim Do Hoon Lim Jeeyun Lee Won Ki Kang John S. MacDonald Chan Hyung Park Se Hoon Park Se-Hoon Lee Kihyun Kim Joon Oh Park Won Seog Kim Chul Won Jung Young Suk Park Young-Hyuck Im Tae Sung Sohn Jae Hyung Noh Jin Seok Heo Yong Il Kim Chul Keun Park Keu | 2005 | International Journal of Radiation Oncology Biology Physics2005，，5： | 1 |
| 7 | Can mean platelet volume predict coronary vasospasm?显示文摘 | Cheol Ung Choi Hong Seog Seo Yun Kyung Kim Jin Oh Na Hong Euy Lim Jin Won Kim Eung Ju Kim Seung-Woon Rha Chang Gyu Park Dong Joo Oh | 2011 | Platelets2011，，3： | 1 |
| 8 | Extranodal nasal type NK/T-cell Lymphoma: Elucidating clinical prognostic factors for risk-based stratification of therapy显示文摘 | Jeeyun Lee Yeon Hee Park Won Seog Kim Seung-Sook Lee Baek-Yeol Ryoo Sung Hyun Yang Keon Woo Park Jung Hoon Kang Joon Oh Park Se Hoon Lee Kihyun Kim Chul Won Jung Young Suk Park Young-Hyuck Im Won Ki Kang Mark H. Lee Young H. Ko Yong Chan Ahn Keunchil Park | 2005 | European Journal of Cancer2005，，10： | 1 |
| 9 | Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer显示文摘 | Yeon Hee Park Jae-Lyun Lee Baek-Yeol Ryoo Min-Hee Ryu Sung Hyun Yang Bong Seog Kim Dong Bok Shin Heung Moon Chang Tae Won Kim Young Jin Yuh Yoon-Koo Kang | 2008 | Cancer Chemotherapy and Pharmacology2008，，4： | 1 |
| 10 | Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: A multicentre, single-arm, phase 2 trial显示文摘 | Seok Jin Kim Dok Hyun Yoon Hye Jin Kang Jin Seok Kim Seong Kyu Park Hyo Jung Kim Jeeyun Lee Baek-Yeol Ryoo Young Hyeh Ko Jooryung Huh Woo Ick Yang Hee Kyung Kim Soo Kee Min Seung-Sook Lee In-Gu Do Cheolwon Suh Won Seog Kim | 2012 | European Journal of Cancer2012，，17： | 1 |
| 11 | Type II enteropathy‐associated T‐cell lymphoma: A multicenter analysis from the Asia Lymphoma Study Group显示文摘 | Eric Tse Harinder Gill Florence Loong Seok Jin Kim Siok‐Bian Ng Tiffany Tang Young‐Hyeh Ko Wee‐Joo Chng Soon‐Thye Lim Won Seog Kim Yok‐Lam Kwong | 2012 | Am J Hematol2012，，7： | 1 |
| 12 | Enteropathy-associated T-cell lymphoma—a clinicopathologic and array comparative genomic hybridization study显示文摘 | Young Hyeh Ko Sivasundaram Karnan Kyeong Mee Kim Cheol Keun Park Eun Suk Kang Young Ho Kim Won Ki Kang Seok Jin Kim Won Seog Kim Woo Yong Lee Ho Kyung Chun Masao Seto | 2010 | Human Pathology2010，，9： | 1 |
| 13 | Capecitabine in combination with Oxaliplatin(XELOX)as a first-line therapy for advance gastric cancer显示文摘 | YEON HEE PARK JAE-LYUN LEE BAEK-YEOL RYOO MIN-HEE RYU SUNG HYUN YANG BONG SEOG KIM DONG BOK SHIN HEUNG MOON CHANG TAE WON KIM YOUNG JIN YUH YOON-KOO KANG | 2008 | Cancer Chemotherapy and pharmacology2008，23，4： | 1 |
| 14 | Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: An 8-week, multicenter, randomized, open-label, dose-titration study in korean patients with hypercholesterolemia显示文摘 | Sang Hak Lee Namsik Chung Jun Kwan Doo-Il Kim Won Ho Kim Chee Jeong Kim Hyun Seung Kim Si Hoon Park Hong Seog Seo Dong Gu Shin Yung Woo Shin Wan-Joo Shim Tae Hoon Ahn Kyeong Ho Yun Myeong-Ho Yoon Kwang-Soo Cha Si-Wan Choi Seong Wook Han Min Su Hyon | 2007 | Clinical Therapeutics2007，，11： | 1 |
| 15 | Antidiabetic effects of extracts from Psidium guajava显示文摘 | Won Keun Oh Chul Ho Lee Myung Sun Lee Eun Young Bae Cheon Bae Sohn Hyuncheol Oh Bo Yeon Kim Jong Seog Ahn | 2004 | Journal of Ethnopharmacology2004，，3： | 1 |
| 16 | Genome-Wide Analysis of DNA Methylation and the Gene Expression Change in Lung Cancer显示文摘 | Yong-Jae Kwon Seog Joo Lee Jae Soo Koh Sung Han Kim Hae Won Lee Moon Chul Kang Jae Bum Bae Young-Joon Kim Jong Ho Park | 2012 | Journal of Thoracic Oncology2012，，1： | 1 |
| 17 | Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer显示文摘 | Yeon Hee Park Jae-Lyun Lee Baek-Yeol Ryoo Min-Hee Ryu Sung Hyun Yang Bong Seog Kim Dong Bok Shin Heung Moon Chang Tae Won Kim Young Jin Yuh Yoon-Koo Kang | 2008 | Cancer Chemotherapy and Pharmacology2008，，4： | 1 |
| 18 | Multiple mucosa-associated lymphoid tissue organs involving marginal zone B cell lymphoma: organ-specific relationships and the prognostic factors. Consortium for improving survival of lymphoma study显示文摘 | Sung Yong Oh Won Seog Kim Jin Seok Kim Seok Jin Kim Suee Lee Dae Ho Lee Jong-Ho Won In Gyu Hwang Min Kyoung Kim Soon Il Lee Yee Soo Chae Deok-Hwan Yang Hye Jin Kang Chul Won Choi Jinny Park Hyo Jung Kim Jung Hye Kwon Ho Sup Lee Gyeong-Won Lee Hyeon Seok E | 2010 | International Journal of Hematology2010，，3： | 1 |
| 19 | Protein tyrosine phosphatase 1B inhibitors from Morus root bark显示文摘 | Long Cui MinKyun Na Hyuncheol Oh Eun Young Bae Dae Gwin Jeong Seong Eon Ryu Sohee Kim Bo Yeon Kim Won Keun Oh Jong Seog Ahn | 2005 | Bioorganic & Medicinal Chemistry Letters2005，，5： | 1 |
| 20 | AS-148: Impact of Statins on 12-Month Clinical Outcomes in Acute ST-Segment Elevation Myocardial Infarction Patients Who Received Thrombolytic Therapy显示文摘 | Seung-Woon Rha Lin Wang Ji Young Park Sureshkumar Ramasamy Byoung Geol Choi Ji Bak Kim Seung Yong Shin Cheol Ung Choi Hong Euy Lim Jin Won Kim Eung Ju Kim Chang Gyu Park Hong Seog Seo Dong Joo Oh Young Keun Ahn Myung Ho Jeong | 2010 | The American Journal of Cardiology2010，，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员